13. Chirila, C., Odom, D., Devercelli, G., Khan, S., Sherif, B., Kaye, J. et al. Meta-analysis <strong>of</strong> <strong>the</strong>association <strong>between</strong> <strong>progression</strong>-free survival and overall survival in metastatic colorectalcancer. International Journal <strong>of</strong> Colorectal Disease 2011;1-12.14. Buyse, M., Burzykowski, T., Carroll, K., Michiels, S., Sargent, D.J., Miller, L.L. et al.Progression-free survival is a surrogate for survival in advanced colorectal cancer. Journal <strong>of</strong>Clinical Oncology 2007; 25(33):5218-5224.15. Burzykowski, T., Buyse, M., Piccart-Gebhart, M.J., Sledge, G., Carmichael, J., Luck, H.J. etal. Evaluation <strong>of</strong> tumor response, disease control, <strong>progression</strong>-free survival, and time to<strong>progression</strong> as potential surrogate end points in metastatic breast cancer. Journal <strong>of</strong> ClinicalOncology 2008; 26(12):1987-1992.16. Halabi, S., Vogelzang, N.J., Ou, S.S., Owzar, K., Archer, L., Small, E.J. Progression-FreeSurvival as a Predictor <strong>of</strong> Overall Survival in Men With Castrate-Resistant Prostate Cancer.Journal <strong>of</strong> Clinical Oncology 2009; 27(17):2766-2771.17. Foster, N.R., Qi, Y., Shi, Q., Krook, J.E., Kugler, J.W., Jett, J.R. et al. Tumor Response andProgression-Free Survival as Potential Surrogate Endpoints for Overall Survival in ExtensiveStage Small-Cell Lung Cancer Findings on <strong>the</strong> Basis <strong>of</strong> North Central Cancer TreatmentGroup Trials. Cancer 2011; 117(6):1262-1271.18. Polley, M.Y., Lamborn, K.R., Chang, S.M., Butowski, N., Clarke, J.L., Prados, M. Six-month<strong>progression</strong>-free survival as an alternative primary efficacy endpoint to overall survival innewly diagnosed glioblastoma patients receiving temozolomide. Neuro-Oncology 2010;12(3):274-282.19. Mandrekar, S.J.P., Qi, Y., Hillman, S.L., Allen Ziegler, K.L., Reuter, N.F., Rowland, K.M. etal. Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer. Journal <strong>of</strong>Thoracic Oncology 2010; 5(1):3-9.20. Heng, D.Y.C.M., Xie, W., Bjarnason, G.A., Vaishampayan, U., Tan, M., Knox, J. et al.Progression-free survival as a predictor <strong>of</strong> overall survival in metastatic renal cell carcinomatreated with contemporary targeted <strong>the</strong>rapy. Cancer 2011; 117(12):2637-2642.21. Wilkerson, J., Fojo, T. Progression-Free Survival Is Simply a Measure <strong>of</strong> a Drug's EffectWhile Administered and Is Not a Surrogate for Overall Survival. Cancer Journal 2009;15(5):379-385.22. Louvet, C., de Gramont, A., Tournigand, C., Artru, P., Maindrault-Goebel, F., Krulik, M.Correlation <strong>between</strong> <strong>progression</strong> free survival and response rate in patients with metastaticcolorectal carcinoma. Cancer 2001; 91(11):2033-2038.23. Miksad, R.A., Zietemann, V., Go<strong>the</strong>, R., Schwarzer, R., Conrads-Frank, A., Schnell-Inderst,P. et al. Progression-free survival as a surrogate endpoint in advanced breast cancer.International Journal <strong>of</strong> Technology Assessment in Health Care 2008; 24(4):371-383.24. Hackshaw, A., Knight, A., Barrett-Lee, P., Leonard, R. Surrogate markers and survival inwomen receiving first-line combination anthracycline chemo<strong>the</strong>rapy for advanced breastcancer. British Journal <strong>of</strong> Cancer 2005; 93(11):1215-1221.36
25. Hotta, K., Kiura, K., Fujiwara, Y., Takigawa, N., Hisamoto, A., Ichihara, E. et al. Role <strong>of</strong>Survival Post-Progression in Phase III Trials <strong>of</strong> Systemic Chemo<strong>the</strong>rapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review. Plos One 2011; 6(11).26. Hotta, K., Fujiwara, Y., Matsuo, K., Kiura, K., Takigawa, N., Tabat, M. et al. Time toProgression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-smallCell Lung Cancer. Journal <strong>of</strong> Thoracic Oncology 2009; 4(3):311-317.27. Tang, P.A., Bentzen, S.M., Chen, E.X., Siu, L.L. Surrogate end points for median overallsurvival in metastatic colorectal cancer: literature-based analysis from 39 randomizedcontrolled trials <strong>of</strong> first-line chemo<strong>the</strong>rapy. Journal <strong>of</strong> Clinical Oncology 2007; 25(29):4562-4568.28. Bowater, R.J., Lilford, P.E., Lilford, R.J. Estimating changes in overall survival using<strong>progression</strong>-free survival in metastatic breast and colorectal cancer. International Journal <strong>of</strong>Technology Assessment in Health Care 2011; 27(3):207-214.29. Anderson, J.R., Cain, K.C., Gelber, R.D. Analysis <strong>of</strong> survival by tumor response and o<strong>the</strong>rcomparisons <strong>of</strong> time-to-event by outcome variables. Journal <strong>of</strong> Clinical Oncology 2008;26(24):3913-3915.30. Broglio, K.R., Berry, D.A. Detecting an overall survival benefit that is derived from<strong>progression</strong>-free survival. Journal <strong>of</strong> <strong>the</strong> National Cancer Institute (Cary) 2009;101(23):1642-1649.37
Change language